Search hospitals > Illinois > Orland Park

University of Chicago Medicine-Orland Park

Claim this profile
Orland Park, Illinois 60462
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Tumors
110 reported clinical trials
26 medical researchers
Photo of University of Chicago Medicine-Orland Park in Orland ParkPhoto of University of Chicago Medicine-Orland Park in Orland ParkPhoto of University of Chicago Medicine-Orland Park in Orland Park

Summary

University of Chicago Medicine-Orland Park is a medical facility located in Orland Park, Illinois. This center is recognized for care of Cancer, Recurrence, Breast Cancer, Adenocarcinoma, Tumors and other specialties. University of Chicago Medicine-Orland Park is involved with conducting 110 clinical trials across 293 conditions. There are 26 research doctors associated with this hospital, such as Rita Nanda, MD, Ardaman Shergill, MD, Christine M. Bestvina, and John Moroney, MD.

Area of expertise

1Cancer
Global Leader
University of Chicago Medicine-Orland Park has run 55 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Recurrence
Global Leader
University of Chicago Medicine-Orland Park has run 19 trials for Recurrence. Some of their research focus areas include:
Stage IV
Stage III
Stage II

Top PIs

Clinical Trials running at University of Chicago Medicine-Orland Park

Breast Cancer
Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Renal Cell Carcinoma
Bladder Carcinoma
Bladder Cancer
Diffuse Large B-Cell Lymphoma
Gallbladder Cancer
Image of trial facility.

Omitting Radiation Therapy

for Breast Cancer

This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Chicago Medicine-Orland Park?
University of Chicago Medicine-Orland Park is a medical facility located in Orland Park, Illinois. This center is recognized for care of Cancer, Recurrence, Breast Cancer, Adenocarcinoma, Tumors and other specialties. University of Chicago Medicine-Orland Park is involved with conducting 110 clinical trials across 293 conditions. There are 26 research doctors associated with this hospital, such as Rita Nanda, MD, Ardaman Shergill, MD, Christine M. Bestvina, and John Moroney, MD.